David Lucchino is an entrepreneur and business leader in the world’s leading life science cluster, the Kendall Square neighborhood, in Cambridge, Massachusetts.

David is co-founder and CEO of Frequency Therapeutics, a clinical-stage, venture-backed company that is advancing a novel way to enlist the body’s native regenerative abilities to treat chronic conditions, including noise-induced hearing loss and diseases of the skin, muscles and gastrointestinal tract.

David is the Chairman of the Board of Directors of MassBio, the voice of the biotechnology industry in Massachusetts representing more than 1,300 companies as well hospitals, research labs and other organizations.

David has a long track record of success as an entrepreneur. He was co-founder and CEO of Semprus BioSciences, a medical device firm that earned numerous FDA clearances and was acquired by a public medical device firm in a $80 million transaction.  He also was the CEO of Entrega Bio, which is developing an oral delivery mechanism for therapeutics typically administered by injection or infusion.

David worked at Polaris Partners and started his life sciences career as a co-founder and managing director of LaunchCyte, a biomedical intellectual property acquisition and development firm that has launched and transacted numerous startup companies.

Mr. Lucchino is a member of the College of Fellows of the American Institute for Medical and Biological Engineering and was appointed by Governor Charlie Baker as a member of the Advisory Council to the Massachusetts Department of Labor Relations.

Mr. Lucchino serves as a trustee of Mt. Auburn Hospital in Cambridge, MA; a trustee of the Multiple Myeloma Research Foundation; a member of the Board of Advisors for Life Science Cares; and a member of the Board of Advisors for the NOLS, which teaches leadership skills through wilderness experiences. He was part of a NOLS expedition that climbed Denali in Alaska.